Coated Mongolian Aneurysm Treatment Study 2

NCT04305704 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-04-26

No results posted yet for this study

Summary

The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under prasugrel.

Conditions

  • Intracranial Aneurysm
  • Aneurysm
  • Vascular Diseases

Sponsors & Collaborators

  • Phenox GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-08
Primary Completion
2023-02-28
Completion
2023-12-30

Countries

  • Mongolia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04305704 on ClinicalTrials.gov